Physician profile
Sanjay Dogra
NPI 1932114634
$6,957.02
in general payments reported to CMS, 2019-2025
17 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $176 · 2021: $1,360 · 2022: $82.73 · 2023: $2,935 · 2024: $162 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,714 · Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,714.28 |
| Food and Beverage | $640.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $1,521.60 | 2023 | |
| Medical Device Business Services, INC. | $1,413.29 | 2023 | |
| Intuitive Surgical, INC. | $973.57 | 2022-2025 | |
| Pulmonx Corporation | $819.55 | 2021-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Ethicon INC. | $694.07 | 2020-2021 | |
| Glaxosmithkline, LLC. | $531.03 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $178.66 | 2019-2021 | |
| Axsome Therapeutics, INC. | $124.74 | 2024 | Sunosi |
| Mylan Specialty L.P. | $123.26 | 2019 | |
| Sunovion Pharmaceuticals INC. | $121.93 | 2019-2020 | |
| Lilly USA, LLC | $121.35 | 2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.44 | 2019 | |
| Covidien LP | $84.94 | 2019 | |
| Eli Lilly and Company | $47.33 | 2019 | |
| Inspire Medical Systems, INC. | $37.54 | 2024 | Inspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $32.90 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Dogra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.